Literature DB >> 15964422

Effects of epigallocatechin gallate on the hemolysis induced by cyclosporine.

H C Kim1, E J Chang, K C Mun.   

Abstract

INTRODUCTION: Hemolysis is one of the side effects of cyclosporine (CsA) therapy, in part due to, increased production of free radical species by CsA. Epigallocatechin gallate (EGCG), which acts as a highly efficient free radical scavenger, may have a protective effect on CsA-induced hemolysis. In this study, we measured the degree of hemolysis of as well as the amounts of hydrogen peroxide level and malondialdehyde produced by normal human erythrocytes (RBCs) incubated with CsA and with EGCG.
METHODS: Human RBCs were incubated as follows. In group 1, 4.2 x 10(6)/mL RBCs were incubated with Cremophore EL. In group 2, the RBCs were incubated with only 167 microg/mL EGCG. In group 3, the RBCs were incubated with 1.67 mg/mL CsA. In group 4, the RBCs were incubated with CsA plus EGCG.
RESULTS: The degree of hemolysis in group 2 (53.8 +/- 3.8) was significantly higher than that in group 1 (7.0 +/- 1.0). The degree of hemolysis in group 3 (86.2 +/- 2.2) was significantly higher than that in group 1 and group 2. The degree of hemolysis in group 4 (74.9 +/- 2.9) was significantly higher than in group 1 and in group 2, but lower than that in group 3. The hydrogen peroxide and malondialdehyde levels paralleled the degree of hemolysis.
CONCLUSIONS: These results suggest that CsA can induce free radical-mediated hemolysis, which can be partially prevented with EGCG.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15964422     DOI: 10.1016/j.transproceed.2005.03.006

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  3 in total

1.  Addition of Epigallocatechin Gallate 400 mg to Sofosbuvir 400 mg + Daclatisvir 60 mg With or Without Ribavirin in Treatment of Patients with Chronic Hepatitis C Improves the Safety Profile: A Pilot Study.

Authors:  Gamal Shiha; Reham Soliman; Mohamed Elbasiony; Noureldien H E Darwish; Shaker A Mousa
Journal:  Sci Rep       Date:  2019-09-19       Impact factor: 4.379

2.  Novel combined single dose anti-hepatitis C therapy: a pilot study.

Authors:  Gamal Shiha; Reham Soliman; Mohamed Elbasiony; Noureldien H E Darwish; Shaker A Mousa
Journal:  Sci Rep       Date:  2021-02-25       Impact factor: 4.379

3.  Interaction of Catechins with Human Erythrocytes.

Authors:  Katarzyna Naparlo; Grzegorz Bartosz; Ireneusz Stefaniuk; Bogumil Cieniek; Miroslaw Soszynski; Izabela Sadowska-Bartosz
Journal:  Molecules       Date:  2020-03-24       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.